PERFORMANCE ALONE.

PERFORMANCE TOGETHER

As combination therapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy—FASLODEX in combination with certain CDK4/6 inhibitors.

PERFORMANCE ALONE.

PERFORMANCE TOGETHER

As combination therapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy—FASLODEX in combination with certain CDK4/6 inhibitors.

As monotherapy for the treatment of HR-positive advanced breast cancer or mBC in postmenopausal women who have endocrine therapy-naïve, HER2-negative disease (FALCON), or disease progression following endocrine therapy (CONFIRM)

HER2=human epidermal growth factor receptor 2; HR=hormone receptor; mBC=metastatic breast cancer.

Reference: 1. FASLODEX® (fulvestrant) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.